标题
Engineered T Cell Therapy for Cancer in the Clinic
作者
关键词
-
出版物
Frontiers in Immunology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-10-11
DOI
10.3389/fimmu.2019.02250
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
- (2019) David Cella et al. LANCET ONCOLOGY
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
- (2019) Fei Yang et al. OncoTargets and Therapy
- NR4A transcription factors limit CAR T cell function in solid tumours
- (2019) Joyce Chen et al. NATURE
- TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion
- (2019) Hyungseok Seo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- From clinical proof-of-concept to commercialization of CAR T cells
- (2018) Boris Calmels et al. DRUG DISCOVERY TODAY
- Anti-VEGF treatment improves neurological function in tumors of the nervous system
- (2018) Na Zhang et al. EXPERIMENTAL NEUROLOGY
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
- (2018) Jianyu Weng et al. Journal of Hematology & Oncology
- T cell senescence and CAR-T cell exhaustion in hematological malignancies
- (2018) Dimitri Kasakovski et al. Journal of Hematology & Oncology
- Driving T-cell immunotherapy to solid tumors
- (2018) Ken Garber NATURE BIOTECHNOLOGY
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
- (2018) Paris Kosti et al. Frontiers in Immunology
- CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity
- (2018) Gray Kueberuwa et al. Molecular Therapy-Oncolytics
- Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
- (2018) Inmaculada Hernandez et al. JAMA Oncology
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
- (2018) Joseph A. Fraietta et al. NATURE
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- New developments in immunotherapy for lymphoma
- (2018) Heyman Benjamin et al. Cancer Biology & Medicine
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Universal CARs, universal T cells, and universal CAR T cells
- (2018) Juanjuan Zhao et al. Journal of Hematology & Oncology
- CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
- (2018) Stephanie Vairy et al. Drug Design Development and Therapy
- Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy
- (2018) Melanie D. Whittington et al. JAMA Oncology
- A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
- (2018) Yiyang Xu et al. Cell Discovery
- Emerging antibodies for the treatment of pancreatic cancer
- (2017) Kalliopi Andrikou et al. EXPERT OPINION ON EMERGING DRUGS
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
- (2017) Tyrel T. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses
- (2017) Eleanor M. Scott et al. MACROMOLECULAR BIOSCIENCE
- Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers
- (2017) Chengcheng Zhang et al. MOLECULAR THERAPY
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- FDA approves first CAR T therapy
- (2017) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- IMMU-17. TRANSGENIC EXPRESSION OF IL15 IMPROVES ANTIGLIOMA ACTIVITY OF IL13RΑ2-CAR T CELLS
- (2017) David Steffin et al. NEURO-ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
- (2017) Zhenguang Wang et al. Protein & Cell
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
- (2017) Irene Scarfò et al. Journal for ImmunoTherapy of Cancer
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice
- (2016) Herbert W. Kavunja et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Driving gene-engineered T cell immunotherapy of cancer
- (2016) Laura A Johnson et al. CELL RESEARCH
- Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches
- (2016) P. Brodt CLINICAL CANCER RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
- (2016) M. V. Maus et al. CLINICAL CANCER RESEARCH
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
- (2016) Drew C. Deniger et al. CLINICAL CANCER RESEARCH
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2016) Yang-min Zhu et al. MEDICINE
- Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes
- (2016) Nishant Mohan et al. MOLECULAR CANCER THERAPEUTICS
- GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
- (2016) Tessa Gargett et al. MOLECULAR THERAPY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
- (2016) Fengtao You et al. Science China-Life Sciences
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
- (2016) Kaichao Feng et al. Science China-Life Sciences
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
- (2016) Xiao-Yi Tang et al. BMJ Open
- Chimeric antigen receptor T-cell therapy for solid tumors
- (2016) Kheng Newick et al. Molecular Therapy-Oncolytics
- LBA-02High Response Rate and PFS with PEGPH20 added to Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase 2 Study
- (2015) A. Hendifar et al. ANNALS OF ONCOLOGY
- Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
- (2015) S. Kageyama et al. CLINICAL CANCER RESEARCH
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
- (2015) S. C. Katz et al. CLINICAL CANCER RESEARCH
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street
- (2015) David M. Barrett et al. JOURNAL OF IMMUNOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Adoptive Immunotherapy for Cancer or Viruses
- (2014) Marcela V. Maus et al. Annual Review of Immunology
- Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
- (2014) Yao Wang et al. CLINICAL IMMUNOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
- (2012) Lana E Kandalaft et al. Journal of Translational Medicine
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
- (2010) C. H. J. Lamers et al. BLOOD
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
- (2010) Maria R Parkhurst et al. MOLECULAR THERAPY
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity
- (2009) P D Peng et al. GENE THERAPY
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
- (2009) Xiao-Song Zhong et al. MOLECULAR THERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started